Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation

Clinical Cancer Research

Volumn 20, Issue 5, 2014, Pages 1366-1374

  Wang, Xin Shelley ^a   Shi, Qiuling ^a   Shah, Nina D ^a   Heijnen, Cobi J ^a   Cohen, Evan N ^a   Reuben, James M ^a   Orlowski, Robert Z ^a   Qazilbash, Muzaffar H ^a   Johnson, Valen E ^a   Williams, Loretta A ^a   Mendoza, Tito R ^a   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MELPHALAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CLINICAL FEATURE; CLINICAL TRIAL; DECREASED APPETITE; DISEASE SEVERITY; DROWSINESS; DRUG MEGADOSE; FATIGUE; FEMALE; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SLEEP DISORDER;

ADULT; AGED; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84895834879     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2442     Document Type: Article

References (26)

1. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9:278-88.
2. Anderson KO, Giralt SA, Mendoza TR, Brown JO, Neumann JL, Mobley GM, et al. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007;39: 759-66.
3. Wang XS, Shi Q, Williams LA, Cleeland CS, Mobley GM, Reuben JM, et al. Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer 2008;113:2102-9.
4. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?Acytokine-immunologic model of cancer symptoms. Cancer 2003;97:2919-25.
5. Dantzer R, Meagher MW, Cleeland CS. Translational approaches to treatment-induced symptoms in cancer patients. Nat Rev Clin Oncol 2012;9:414-26.
6. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008;26:971-82.
7. Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010;24:968-74.
8. Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 2012;26:699-705.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
10. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.
11. Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634-46.
12. Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, et al. Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol 2013;6:13.
13. Lee BN, Dantzer R, Langley KE, Bennett GJ, Dougherty PM, Dunn AJ, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 2004;11: 279-92.
14. Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 2005;257:139-55.
15. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106:2437-44.
16. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res 2011;11:163-9.
17. Fairclough DL, Wang XS. Understanding the correlations between biologic and symptom measures over time. In:Lenderking WR, Revicki DA, editors. Advancing health outcomes research methods and clinical applications. McLean, VA: Degnon Associates; 2005. p. 177-90.
18. McGregor BA, Syrjala KL, Dolan ED, Langer SL, Redman M. The effect of pre-transplant distress on immune reconstitution among adult autologous hematopoietic cell transplantation patients. Brain Behav Immun 2013;30Suppl:S142-8.
19. Ferrara JL. Cytokine inhibitors and graft-versus-host disease. Ann N Y Acad Sci 1995;770:227-36.
20. Reikvam H, Mosevoll KA, Melve GK, Günther CC, Sjo M, Bentsen PT, et al. The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biol Blood Marrow Transplant 2012;18:190-9.
21. Laird NM, Donnelly C, Ware JH. Longitudinal studies with continuous responses. Stat Methods Med Res 1992;1:225-47.
22. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007;21:413-27.
23. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. Spatial variability. In: Littell RC, Milliken GA, Stroup WW, Wolfinger RD, editors. SAS system for mixed models. Cary, NC: SAS Institute, Inc.; 1996. p. 303-30.
24. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989;73:1915-24.
25. Bilbo SD, Schwarz JM. The immune system and developmental programming of brain and behavior. Front Neuroendocrinol 2012; 33:267-86.
26. Poon DC, Ho YS, Chiu K, Chang RC. Cytokines: how important are they in mediating sickness? Neurosci Biobehav Rev 2013;37:1-10.